Oral Cannabidiol for Tobacco Cessation
NCT05445804
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Cannabidiol is a compound found in cannabis plants that is well tolerated, has low abuse liability, and might be an effective medication to promote tobacco cessation. This clinical study will use a validated approach for screening tobacco cessation medications to determine if oral cannabidiol increases short-term tobacco abstinence, and evaluate mechanisms that might explain how cannabidiol alters smoking behavior. Results from this study will provide data on the therapeutic potential of cannabidiol for tobacco cessation.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Tobacco Use
- Tobacco Smoking
- Tobacco Dependence
- Tobacco Use Disorder
- Tobacco Use Cessation
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Johns Hopkins University
- Last updated on ClinicalTrials.gov
- January 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- Johns Hopkins Behavioral Pharmacology Research Unit · Baltimore, MD
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.